



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Multimodality quantitative assessments of myocardial perfusion using dynamic contrast enhanced magnetic resonance and 15O-labelled water positron emission tomography imaging.

Citation for published version:

Papanastasiou, G, Williams, M, Dweck, M, Mirsadraee, S, Weir, NW, Fletcher, AM, Lucatelli, C, Patel, D, van Beek, E, Newby, D & Semple, S 2018, 'Multimodality quantitative assessments of myocardial perfusion using dynamic contrast enhanced magnetic resonance and 15O-labelled water positron emission tomography imaging.', IEEE Transactions on Radiation and Plasma Medical Sciences.
<https://doi.org/10.1109/TRPMS.2018.2796626>

Digital Object Identifier (DOI):

[10.1109/TRPMS.2018.2796626](https://doi.org/10.1109/TRPMS.2018.2796626)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

IEEE Transactions on Radiation and Plasma Medical Sciences

Publisher Rights Statement:

Author's peer reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Multimodality quantitative assessments of myocardial perfusion using dynamic contrast enhanced magnetic resonance and ^{15}O -labelled water positron emission tomography imaging.

G. Papanastasiou, M. C. Williams, M. R. Dweck, S. Mirsadraee, N. Weir, A. Fletcher, C. Lucatelli, D. Patel, E. J. R. van Beek, D. E. Newby, and S. I. K. Semple.

Abstract—Kinetic modelling of myocardial perfusion imaging data allows the absolute quantification of myocardial blood flow (MBF) and can improve the diagnosis and clinical assessment of coronary artery disease (CAD). Positron emission tomography (PET) imaging is considered the reference standard technique for absolute quantification, whilst oxygen-15 (^{15}O)-water has been extensively implemented for MBF quantification. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) has also been used for MBF quantification and showed comparable diagnostic performance against (^{15}O)-water PET studies. We investigated for the first time the diagnostic performance of two different PET MBF analysis softwares PMOD and Carimas, for obstructive CAD detection against invasive clinical standard methods in 20 patients with known or suspected CAD. Fermi and distributed parameter modelling-derived MBF quantification from DCE-MRI was also compared against (^{15}O)-water PET, in a subgroup of 6 patients. The sensitivity and specificity for PMOD was significantly superior for obstructive CAD detection in both per vessel (0.83, 0.90) and per patient (0.86, 0.75) analysis, against Carimas (0.75, 0.65), (0.81, 0.70), respectively. We showed strong, significant correlations between MR and PET MBF quantifications ($r=0.83-0.92$). However, DP and PMOD analysis demonstrated comparable and higher haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD, against Fermi and Carimas analysis. Our MR method assessments against the optimum PET reference standard technique for perfusion analysis showed promising results in per segment level and can support further multi-modality assessments in larger patient cohorts. Further MR against PET assessments may help to determine their comparative diagnostic performance for obstructive CAD detection.

Keywords— coronary artery disease, DCE-MRI, kinetic modelling, ^{15}O -water PET.

This work was financially supported by the British Heart Foundation (GP by the RE/08/001/23904, MCW, MRD and DEN by the FS/11/014, CH/09/002). DEN is the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA). EJRvB is supported by the Scottish Imaging Network (www.sinapse.ac.uk). The Edinburgh Imaging facility QMRI and Wellcome Trust Clinical Research Facility (Edinburgh) are supported by the National Health Service Research Scotland (NRS). The Centre for Cardiovascular Science is the recipient of a British Heart Foundation Centre of Research Excellence Award (RE/08/001).

GP, MCW, MRD, DEN and SIKS are with the Edinburgh Imaging facility QMRI (EIF-QMRI) and the Centre for Cardiovascular Science, Edinburgh, EH16 4TJ, UK (e-mails: g.papanas@ed.ac.uk, michelle.williams@ed.ac.uk, mdweck@exseed.ed.ac.uk, d.e.newby@ed.ac.uk, scott.semple@ed.ac.uk).

DP is with the Department of Radiology, Royal Infirmary of Edinburgh, EH16 4SA, UK (dilip.patel@nhslothian.scot.nhs.uk).

NW, AF, CL and EJRvB are with the EIF-QMRI (nick.weir@ed.ac.uk, alison.fletcher@ed.ac.uk, christophe.lucatelli@ed.ac.uk, edwin-vanbeek@ed.ac.uk). SM was with the EIF-QMRI and is now with the Royal Brompton and Harefield Hospitals NHS Trust, London, SW3 6NP, UK (saeed.mirsadraee@ed.ac.uk).

I. INTRODUCTION

Myocardial ischaemia is an essential prognostic determinant in coronary artery disease (CAD) and non-invasive methods for ischaemia assessment are important for the clinical management of patients with known or suspected CAD [1]. The current non-invasive clinical standard assessment for myocardial ischaemia is based on visual estimates from perfusion imaging data which are limited to identifying regional perfusion changes. The diagnostic performance of visual estimates is particularly compromised in conditions where MBF is diffusely abnormal, such as in multi-vessel disease, or where microvascular dysfunction may be present [2]. Kinetic modelling of myocardial perfusion imaging data can allow the absolute quantification of myocardial blood flow (MBF), which has the potential to improve the diagnosis of coronary artery disease (CAD), the assessment of coronary microcirculation and to precisely assess MBF changes following therapeutic interventions [2], [3].

Positron emission tomography (PET) imaging benefits from a direct relationship between signal intensity and the radioactivity concentration in the tissue of interest and is considered the reference standard technique for absolute quantification of MBF [4]. In the context of MBF quantification, previous studies demonstrated the applicability of oxygen-15 (^{15}O)-water in PET perfusion imaging [4], [5]. For a metabolically inert freely diffusible tracer such as ^{15}O -water, single-tissue compartmental models are commonly used for MBF quantification without the need for radio-metabolite correction in the arterial blood [5], [6]. However, additional post-processing techniques are required to correct for spill-over effects between the left, right ventricular arterial blood and myocardial tissue compartments and for the low signal gradient between myocardial tissue and arterial blood [2], [4], [5], [6]. Perfusion analysis software implement different methods for spill-over correction and myocardial tissue delineation [4], [7], [8]. Although strong correlations in MBF quantification derived from different available PET perfusion analysis software (Carimas versus Cardiac VUer) have been previously shown [9], there is no previous work comparing the diagnostic ability of different perfusion analysis softwares to detect haemodynamic differences in the presence of obstructive CAD.

Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) using gadolinium-based extracellular contrast agents, has also been used to derive absolute quantification of MBF. Quantitative MR studies have previously shown comparable diagnostic performance for the detection of obstructive CAD [10], [11], [12] compared to quantitative ^{15}O -

water PET [13], [14], [15]. Various MR models have been used to describe the kinetics of gadolinium-based contrast agents through the myocardium. Their diagnostic performance in detecting obstructive CAD has been assessed, with Fermi deconvolution modelling showing high diagnostic accuracy and being the most established approach [3], [10], [11]. The Fermi model is an empirical-mathematical model used to estimate MBF from MR perfusion data during first-pass of gadolinium-based extracellular contrast agents [10], [12]. Our group recently demonstrated that distributed parameter (DP) deconvolution modelling showed superior diagnostic performance against Fermi modelling for the detection of obstructive CAD using 3T MR and our results compared favourably against previous MR studies [12]. The DP model is based on tracer kinetics analysis and it can provide MBF quantification and additional information about coronary vascularity and permeability, such as estimates of intravascular space, extravascular-extracellular space, extraction fraction, permeability surface area product and volume of distribution [12], [16], [17]. MR-derived MBF has been assessed against PET-derived MBF quantification in patients with CAD by using ammonia-13 (^{13}N) and rubidium-82 (^{82}Rb), which showed weak [18] and stronger [19] correlations, respectively. Despite these first multi-modality MBF comparisons, Fermi- and DP modelling-derived MBF quantification from DCE-MR data have not been assessed against ^{15}O -water PET data in patients with CAD.

The objectives of this study were two-fold. We evaluated the diagnostic performance of 2 dedicated software packages, Carimas and PMOD, to detect obstructive CAD against the current clinical standard assessments of invasive coronary angiography and fractional flow reserve in a pilot population. We also assessed for the first-time Fermi- and DP modelling-derived MBF quantification from DCE-MRI against ^{15}O -water PET data, acquired in patients with CAD.

II. METHODS

A. Study population

The study was performed with the approval of the institutional research ethics committee and in accordance with the Declaration of Helsinki, as previously described [20]. Following informed consent, ^{15}O -water PET was acquired in 20 patients with history of stable angina and known or suspected CAD. Results are also presented here for a subset of 6 subjects who agreed to receive DCE-MRI, prior to standard clinical invasive CAD assessments (maximum interval between PET and MR imaging was 7 days). All subjects were instructed to abstain from caffeine for 12h before PET and MR imaging, which acts as an adenosine receptor antagonist and can otherwise affect adenosine-induced stress imaging [11], [14]. Exclusion criteria for subject recruitment included history of severely compromised renal function (serum creatinine greater than 2.26 mg/dL or glomerular filtration rate ≤ 30 mL/min), pregnancy and contraindications to adenosine or MR imaging. All patients underwent invasive coronary angiography and fractional flow reserve.

B. Cardiac positron emission tomography

Rest and adenosine stress ^{15}O -water PET was performed using a hybrid PET-CT scanner (128-multidetector Biograph mCT, Siemens Medical Systems, Germany), as previously described [20]. Attenuation correction computed tomography imaging maps was acquired before rest and stress imaging. ^{15}O -water was produced by an on-site cyclotron (PETtrace 8, GE Healthcare, UK) and a radiowater generator (Hydex Oy, Finland) generated the ^{15}O -water bolus. For rest imaging, a target of 500 MBq ^{15}O -water bolus was injected intravenously over 15 s and the venous line was then flushed for another 2 min. The dynamic acquisition was performed over 5 min (14 frames \times 5 s, 3 frames \times 10 s, 3 frames \times 20 and 4 frames \times 30 s).

Following suitable radioactivity decay (of approximately 10 min), stress imaging was performed with intravenously administering adenosine for 4 min (140 $\mu\text{g}/\text{kg}/\text{min}$, Adenoscan, Sanofi Aventis) [13], [20]. The above protocol was then repeated using a further dose of 500 MBq ^{15}O -water bolus. Dynamic emission images were reconstructed using the standard UltraHD algorithm (Siemens Medical Systems, Germany) with a zoom of 2.00, matrix 128 \times 128, voxels 3.18 \times 3.18 \times 3 mm.

C. Cardiac magnetic resonance imaging

DCE-MRI imaging was acquired in a 3T Verio imaging system (Siemens, Healthcare GmbH, Erlangen, Germany) using electrocardiogram-gating, as previously described [12]. Standard cardiac imaging planes and a short axis stack of left ventricular cine data were acquired using routine steady state free precession (TrueFISP) acquisitions. Modified Look-Locker inversion recovery (MOLLI) T_1 maps were acquired using the Siemens Works in Progress Package #448, Quantitative Cardiac Parameter Mapping [21].

Stress imaging was performed by implementing the same adenosine infusion protocol as described above for 4 min [10], [12]. 50 dynamic perfusion images were obtained at diastole across 3 short-axis view slices, covering 16 of the standard myocardial segments [22]. For dynamic imaging, a turbo-fast low angle shot (FLASH) saturation recovery prepared single-shot gradient echo pulse sequence was used with imaging parameters: flip angle 12°, repetition time/ echo time 2.20 ms/1.07 ms, slice thickness 8 mm, preparation pulse delay to central line of k-space 100 ms, matrix size 192 \times 108 and FoV 330 mm \times 440 mm. Parallel imaging was performed with the application of GRAPPA (accelerator factor of 3) and partial Fourier acquisition of 0.75, which led to 48-phase encoding lines for each dynamic frame. An intravenous bolus of 0.05 mmol/kg of a gadolinium-based contrast agent (Gadovist, Bayer Healthcare) followed by 20 mL of 0.9% saline (Medrad Spectris Solaris, Medrad, USA) was injected at 4 mL/s using an MR compatible pump injector (Spectris Solaris, Medrad, Bayer). To allow clearance of residual contrast agent, rest perfusion imaging was performed 15 min after stress imaging, with the same acquisition protocol for all 6 subjects.

D. Invasive coronary angiography and fractional flow reserve

Subjects underwent invasive coronary angiography and fractional flow reserve (clinical reference standard

assessments) at the Royal Infirmary of Edinburgh. Invasive coronary angiography was performed via the radial artery as per standard clinical practice [20], [23]. Fractional flow reserve was assessed for major epicardial vessels and defined as the ratio between distal coronary pressure and aortic pressure measured simultaneously at maximal adenosine-induced (intravenous 140 µg/kg/min) hyperaemia [23]. Obstructive CAD was defined as luminal stenosis $\geq 70\%$ on invasive coronary angiography alone, or luminal stenosis $\geq 50\%$ and fractional flow reserve ≤ 0.80 [12], [20]. (No, minor or non)-obstructive CAD was defined as luminal stenosis $< 50\%$ or luminal stenosis $\geq 50\%$ and fractional flow reserve > 0.80 [12], [20].

E. Quantitative ^{15}O -water PET analysis

^{15}O -water PET data were analysed with 2 dedicated softwares (Carimas 2.9, www.turkupetcentre.net, Finland; PMOD 3.7, www.pmod.com, Switzerland), using single-tissue compartment modelling. The single-tissue compartment model can be mathematically described by:

$$\frac{dC_t(t)}{dt} = \text{MBF} \cdot C_a(t) - \frac{\text{MBF}}{p} C_t(t) \quad (1)$$

where $C_t(t)$, $C_a(t)$ are the radioactivity concentrations extracted by the myocardial tissue and the arterial blood from the left ventricular blood pool respectively and p is the partition coefficient of ^{15}O -water (i.e. myocardial to blood radioactivity concentration at equilibrium-when the net tracer flux between the compartments is zero; a constant value of 0.95 mL/mL for Carimas [7] and of 0.96 mL/mL for PMOD modelling [24] were used).

Myocardial contours were defined in short axis views, automatically with manual adjustment on digital subtraction images in Carimas [7], and semi-automatically with manual adjustment on images generated by factor analysis in PMOD [24]. In Carimas, digital subtraction images were automatically generated. For factor analysis in PMOD, volumes of interest were initially outlined within the left and right lungs, from which an average lung time activity curve was extracted. By time-shifting this lung time activity curve (automated time shift of -5 and 5 seconds for the right and left ventricle respectively), approximations of two synthetic time activity curves in the right and left ventricle were derived. A third synthetic time activity curve corresponding to myocardial uptake was then calculated by solving the single-tissue compartment model with the shifted lung time activity curve (8 seconds) and by using a mean MBF value of 1 mL/min/mL [24]. All synthetic time activity curves were then used to automatically estimate weighted factors for the myocardium and left-ventricular blood pool for each dynamic frame, as described by Hermansen *et al.* and factor analysis images were generated [25].

Carimas and PMOD performed correction for spill-over fractions from the left [7] and left and right ventricles [24], respectively. In Carimas post-processing, the measured radioactivity concentration derived from the images was expressed as a function of true radioactivity (radioactivity without the spill-over fractions) in the myocardium and left ventricular blood pool, as described in the following system of

equations:

$$C_t(t) = \text{TF} \cdot C_{tt}(t) + V_a \cdot C_{ta}(t), C_a(t) = \beta \cdot C_{ta}(t) + (1 - \beta) \cdot C_{tt}(t) \quad (2)$$

where TF, C_{tt} , V_a , C_{ta} and β are the perfusable tissue fraction and true radioactivity in the myocardial tissue, the arterial vascular space (including the spill-over from the left ventricle blood pool), the true radioactivity in the left ventricular blood pool and the recovery coefficient (i.e. the ratio of measured to known radioactivity, a constant value of 0.93 was used), respectively. MBF quantification in Carimas was then performed in a 2-step process. Following substitutions in equations (1), (2) and integration, the first operational equation was derived, which is a function of measured radioactivities in the left ventricular blood pool and myocardial tissue and fitted in a time activity curve extracted from the whole (non-segmented) myocardium, using multilinear regression analysis for model fitting (see Table I) [26]. This first step allowed the calculation of the true radioactivity concentration in the left ventricular blood pool C_{ta} . By solving for $C_{tt}(t)$ in the former expression of the system equation (2), integrating and substituting into equation (1), the final operational equation (second step) was then derived which was expressed as a function of true radioactivity $C_{ta}(t)$ (measured from step 1) in the left ventricular blood pool (Table I). From the fitted parameters K_1' , k_2' and V_{fit}' of this operational equation MBF, TF and V_a were calculated and MBF parametric maps (per pixel analysis) were generated. Mathematical derivations for true tissue radioactivity C_{tt} , true radioactivity in the left ventricular blood pool C_{ta} as well as for MBF, TF, V_a calculations and explicit mathematical processing in Carimas, are further described in the Turku PET Centre Modelling report website link (www.Turkupetcentre.net/reports/tpcmod0005.pdf).

In PMOD, by numerically integrating equation (1) and incorporating the spill-over corrections, the operational equation was derived (Table I) and fitted to the time activity curves extracted from myocardial tissue regions of interest using iterative nonlinear least square fitting (1-step process) [24]. In PMOD, the operational equation was expressed in terms of the fitted parameters TF, V_{LV} , V_{RV} and C_{aRV} : perfusable tissue fraction in the myocardial tissue, spill-over fraction from the left ventricle, spill-over fraction from the right ventricle and radioactivity concentration in the right ventricle blood pool, respectively. Spill-over correction from the right ventricle (V_{RV}) was fitted for septal myocardial segments and was set to zero for non-septal myocardial areas. Details about PMOD post-processing are further described in the PMOD website link (doc.pmod.com/PDF/PKIN.pdf). A list of notations for all kinetic modelling parameters is summarised in Supplementary file 1.

F. Quantitative DCE-MRI analysis

Endocardial and epicardial MR contours were manually outlined using validated cardiac image analysis software (QMass, Medis, The Netherlands). Myocardial and arterial input function signal intensity-time curves were converted to gadolinium concentration-time curves using the method of Larsson *et al.* [27] as previously described [10], [12], [28]. According to this, the longitudinal relaxation rate R_1 ($1/T_1$)

changes linearly as a function of contrast agent concentration influx $C(t)$ in the tissue at time t , multiplied by its relaxivity r_1 :

$$\Delta R_1 = C(t) \cdot r_1 \quad (3)$$

where

$$\Delta R_1 = R_1(t) - R_1(0) = \frac{1}{T_1(t)} - \frac{1}{T_1(0)}$$

$T_1(0)$ is the native longitudinal relaxation rate and $T_1(t)$ is the longitudinal relaxation rate at time t of contrast enhancement. $R_1(t)$ can be calculated by adapting the MR signal equation for the saturation recovery prepared single-shot FLASH sequence [10], [28]:

$$S(t) = \Psi \cdot f(R_1(t), PD, n) \quad (4)$$

where $S(t)$ is the equilibrium signal intensity at time t , Ψ is a calibration constant dependent on instrument conditions such as the receiver gain, the proton density and the flip angle α . PD is the pre-pulse delay which is the time between saturation pulse and the central line of k -space, n is the number of applied pulses of flip angle α . Ψ can initially be calculated from equation (4) using native $T_1(0)$ (measured with MOLLI [21]). $R_1(t)$ at time t of contrast enhancement can then be calculated from equation (4), using Ψ and $S(t)$ values extracted from the same region of interest. Contrast agent concentration-time curves can then be calculated using equation (3).

Model-dependent deconvolution analysis was implemented to measure MBF using Fermi and 1-barrier 2-region DP functions as previously described [12]. Fermi parameterisation is an empirical 3-parameter model fit in which τ_0 defines the width of the initial plateau of the tissue impulse response before it decays mono-exponentially at a rate given by the parameter k (see fitted parameters of Fermi function in Table I) [29]. The Fermi model is fitted to the first-pass phase of contrast enhancement. This is estimated by setting the endpoint at the contrast agent concentration minimum in the arterial input function, before the recirculation component begins (this range varies from patient to patient and is commonly in the range between 20-35 dynamic frames) [12]. DP parameterisation is a 4-parameter model fit based on tracer kinetics analysis and its tissue impulse response is expressed in terms of the fitted parameters T , T_c , T_e : T is mean overall transit time, T_c is mean capillary transit time, T_e is mean interstitial (i.e. extravascular-extracellular) transit time (Table I). DP modelling describes the intravascular space as a plug flow system, whilst assumes no axial indicator transport in the extravascular-extracellular space [16], [17]. The third and fourth fitted parameter for Fermi and DP deconvolution analysis respectively was MBF. DP model fitting was performed in the Laplace domain to avoid the discontinuities of the time step-function that can be present when fitting the DP model in the time domain [30]. To account for the time delay (between the onset of contrast enhancement in the blood pool and the myocardium), both models were fitted to the data multiple times from zero to six times the temporal resolution starting from the onset of contrast enhancement in the blood pool and the time delay reaching the optimal χ^2 fit to the data was used in the analysis.

A standardised American Heart Association (AHA) 16-segment model of the heart was generated across all modelling applications [22]. In Carimas, the per pixel analysis was averaged for each of the 16-myocardial segments. For both ^{15}O -water PET and DCE-MR analysis, myocardial perfusion

reserve (MPR) was also calculated by dividing the hyperaemic by the resting MBF. MBF and MPR were quantified for each of the 16 myocardial segments and were then averaged per epicardial vessel territory (vessel territories corresponded to the three main coronary vessels, defined according to the 16 segment model [22]). Mean values for MBF at stress and MPR were classified accordingly in two groups for per vessel and per patient based analysis (see classification in the results section).

G. Statistical analysis

Blinded and independent analysis of ^{15}O -water PET and DCE-MRI data was performed using dedicated statistics software (R Foundation for statistical computing, Vienna, Austria; MedCalc Software, Ostend, Belgium). Linear regression and Pearson's correlation coefficients were used to investigate correlations in MBF estimates between different modelling applications, for both ^{15}O -water PET and DCE-MRI, in a per segment and per vessel basis. Bland Altman analysis was implemented to investigate systematic bias between all modelling applications. Haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD and between all modelling applications in a per segment basis, were investigated by implementing two sample t-test (two-sided P value <0.05 were considered significant). For the Carimas versus PMOD comparison, receiver-operating characteristic (ROC) analysis was used on a per vessel and per patient basis to determine threshold values for absolute MBF at stress and MPR with the greatest sensitivity and specificity to detect obstructive versus (no, minor or non)-obstructive CAD (Group 2 versus Group 1, see Results). The area under the curve (AUC) was calculated using trapezoidal numerical integration and a DeLong *et al.* nonparametric comparison was performed to compare the diagnostic performance of ^{15}O -water PET quantitative methods [31]. The maximal Youden Index was used to determine the optimal threshold values [10], [12].

III. RESULTS

The baseline characteristics of the full patient cohort are presented in Table II. Quantitative ^{15}O -water PET analysis was performed in 20 patients, in which the diagnostic performance of Carimas versus PMOD in detecting obstructive CAD was investigated. For 6 of these patients, quantitative DCE-MRI analysis was also performed and correlations and agreements in MBF measurements were investigated against ^{15}O -water PET.

For each subject, MBF quantification across all 4 modelling methods was performed for each of the 16 myocardial segments, in per segment analysis. Myocardial segments with (no, minor or non)-obstructive and obstructive CAD were then classified based on the invasive coronary angiography and fractional flow reserve data, in Groups 1 and 2, respectively. In per vessel analysis, segmental MBF values were averaged per epicardial vessel territory (three main coronary vessels, as per the 16-segment AHA model) [10], [15], [22]. Vessel territories with (no, minor or non)-obstructive CAD were classified in Group 1 and vessels with obstructive CAD were classified in Group 2. For per patient analysis, patients with all

vessel territories detected with (no, minor or non)-obstructive CAD were classified in Group 1, whilst patients with at least one vessel identified with obstructive CAD, were classified in Group 2 [12].

A. Carimas versus PMOD analysis

Quantitative ^{15}O -water PET analysis was performed in 60 vessel territories in total (20 patients, 3 vessel territories each). 7 patients had at least one vessel identified with obstructive CAD: 3 patients had 1-vessel disease, 3 had 2-vessel disease and 1 had 3-vessel disease. Examples of model fitting and arterial input functions from both modelling approaches are presented in Fig. 2.

On linear regression and Pearson's correlation, PMOD and Carimas-derived MBF showed strong, significant correlations ($P < 0.001$), in both per segment ($r = 0.88$) and per vessel ($r = 0.91$) analysis. Carimas overestimated PMOD MBF estimates at stress ($P < 0.05$), whilst underestimated PMOD MBF estimates at rest ($P < 0.01$).

On Bland Altman analysis, the average bias was calculated as the Carimas-derived estimates minus the PMOD modelling-derived estimates. The systematic bias was low in both per segment and per vessel basis: 0.16 (-1.18, 1.50) versus 0.16 (-0.95, 1.28), respectively.

Haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD were initially assessed in a per segment basis. Significant differences in stress MBF values between myocardial segments classified in Group 1 versus Group 2 were higher (4 orders of magnitude) for PMOD modelling against Carimas modelling, respectively ($P < 0.0001$).

ROC analysis curves were subsequently investigated in per vessel and per patient analysis, shown in Fig. 3. Mean (SD) values for Carimas and PMOD-derived MBF and MPR in Groups 1 and 2 for per vessel analysis are shown in Table III. All haemodynamic thresholds estimated on ROC analysis are presented in Table IV. In per vessel ROC analysis, the AUCs for PMOD were significantly higher compared to Carimas modelling, for both MBF at stress and MPR (Table IV). The diagnostic performance of PMOD consistently outperformed Carimas modelling (Table IV).

Mean (SD) values for Carimas and PMOD-derived MBF and MPR in Groups 1 and 2 for per patient analysis are presented in Table III. In per patient ROC analysis, the AUCs for PMOD were significantly higher whilst the diagnostic performance was consistently superior for PMOD modelling compared to Carimas modelling, for both MBF at stress and MPR (Table IV).

B. DCE-MRI versus ^{15}O -water PET

Quantitative ^{15}O -water PET against DCE-MRI analysis was performed in 18 vessel territories in total (6 patients, 3 vessel territories each). Mean values (SD) and significant differences for all modelling applications, for Groups 1 and 2, are shown in Fig. 4. Significant differences between Groups 1 and 2 were equivalent (P values in the same order of magnitude) for DP against PMOD modelling (Fig. 4, $P < 0.0001$). Significant differences were higher (2 orders of magnitude) for DP and PMOD modelling against Carimas and Fermi modelling, respectively (Fig. 4, $P < 0.0001$). An example file presenting

per segment analysis across all models for a patient with obstructive CAD is shown in the Supplementary file 2.

There were no significant differences between DP, Carimas, and PMOD modelling-derived MBF values at stress. Fermi modelling significantly overestimated MBF compared with all other modelling applications, both at stress and rest ($P < 0.01$). DP and Fermi modelling-derived values overestimated Carimas and PMOD modelling-derived values at rest ($P < 0.001$).

On linear regression and Pearson's correlation analysis, MBF estimates derived from ^{15}O -water PET and DCE-MRI data, were initially separately assessed. Carimas versus PMOD MBF values, as well as DP versus Fermi MBF values, showed significant correlations in per segment and per vessel analysis (Table V, $P < 0.001$).

On Bland Altman analysis, the average bias was calculated as the Carimas-derived estimates minus the PMOD modelling-derived estimates for ^{15}O -water PET data; and Fermi modelling-derived estimates minus the DP modelling-derived estimates for DCE-MRI data (Table V). The systematic bias was low, mainly for ^{15}O -water PET data, which was eliminated in per vessel analysis.

Subsequently, MBF measurements from DP and Fermi modelling from DCE-MRI data were compared against measurements from Carimas and PMOD modelling from ^{15}O -water PET data. Similarly, there were significant ($P < 0.001$) correlations for all comparisons, whilst DP and Fermi modelling showed consistently better correlations with PMOD modelling (Fig. 5), compared to Carimas analysis (Table V).

On Bland Altman analysis, the average bias was calculated as PMOD- and Carimas modelling-derived estimates minus DP modelling-derived estimates; and the Fermi modelling-derived estimates minus the PMOD- and Carimas-modelling-derived estimates (Table V). The lowest systematic bias was observed between PMOD and DP-modelling derived MBF, although with broader limits of agreement, compared to Fermi modelling (Table V, Fig. 5).

IV. DISCUSSION

The main outcomes of this study demonstrated that PMOD showed higher haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD in per segment based analysis, as well as consistently outperforming Carimas modelling in both per vessel and per patient analysis. Beyond strong, significant correlations across all MR versus PET comparisons, DP and PMOD analysis showed comparable and higher haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD, against Fermi and Carimas analysis.

A. Carimas versus PMOD

To date, this is the first study assessing diagnostic performance for the detection of obstructive CAD, using more than one perfusion analysis software. Our correlation coefficients for Carimas versus PMOD estimates are in agreement with similar comparisons performed in ^{15}O -water PET [4] and in ^{82}Rb -rubidium PET [32], which showed good correlations between different cardiac PET perfusion quantification software. Despite the larger patient cohorts

previously analysed, none of these studies compared the diagnostic ability of the different software examined in detecting reduced blood flow in the presence of obstructive CAD. In our pilot cohort, we assessed haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD in per segment analysis, as well as performed full diagnostic performance in per vessel and per patient level on ROC analysis. We demonstrated that PMOD consistently showed higher haemodynamic differences and superior diagnostic performance in detecting obstructive CAD, compared with Carimas. These results indicate that it may be important to fully assess haemodynamic differences and diagnostic performance, beyond just MBF cross-correlations, when different perfusion softwares are compared.

The diagnostic performance for PMOD was in agreement with a previous ^{15}O -water PET study [14], whilst compared favourably against other findings on a per vessel [33], or per patient basis [8]. The highest diagnostic performance for the detection of obstructive CAD was reached by PMOD-derived MBF at stress in per vessel analysis, which is consistent with a previous ^{15}O -water study where the PMOD-derived sensitivity and specificity were higher in per vessel compared to per patient based analysis [33]. Moreover, the diagnostic performance of MBF at stress was consistently higher compared to MPR for both Carimas and PMOD, as previously demonstrated [8], [15], [33]. In this work, a small pilot cohort was investigated with a low number of patients with obstructive and multi-vessel CAD. Microvascular dysfunction that may be present in patients with minor or non-obstructive CAD (see risk factors in Table II: rates for hypertension, hypercholesterolemia, ex-smokers, re-vascularisation [12], [14]), can also lead to MBF reductions, which in turn can compromise the specificity for the detection of obstructive CAD-specific MBF reductions [12]. We showed that Carimas overestimated PMOD estimates at stress hence, any MBF overestimations in myocardial segments classified with obstructive CAD could explain its lower sensitivity versus PMOD, in our data. These factors together with differences in patient cohorts and acquisition protocols can explain the lower diagnostic performance detected for the case of Carimas modelling, in comparison with a previous study which used the same software in a larger patient cohort (38 out of 104 patients scanned had obstructive CAD) and higher ^{15}O -water doses (maximum of 1100 MBq for each ^{15}O -water injection) [13].

Our haemodynamic thresholds on ROC analysis for PMOD and Carimas-derived MBF (Table V) were consistent with previous ^{15}O -water PET studies which identified thresholds in the range between 1.85-2.50 mL/min/mL, for both per vessel and per patient based analyses [8], [13], [14], [33], [34]. Furthermore, these thresholds agree with Fermi (2.49, 2.60 mL/min/mL) and DP (1.75, 2.00 mL/min/mL) modelling-derived thresholds in per vessel and per patient analysis respectively, estimated by our group [12]. Differences in ^{15}O -water doses, PET protocols and scanners, image reconstruction, post-processing techniques and angiographic thresholds defining obstructive CAD can explain any haemodynamic threshold variations between ^{15}O -water PET studies, including the current work [13], [33]. We also demonstrated that Carimas overestimated and underestimated

PMOD estimates at stress and rest respectively, which can explain the higher threshold values identified for Carimas-derived MPRs, in both per vessel and per patient analysis.

Technical disparities between Carimas and PMOD can interpret the diagnostic performance differences demonstrated. Although no spill-over correction from the right ventricle in Carimas means that it would mainly affect MBF measurements in septal myocardial segments (anatomically located between the left and right ventricle), it also overestimated PMOD MBF values at stress in non-septal areas. A considerable disparity between Carimas and PMOD post-processing, is the pixel by pixel based (using a linear least square approach described in [26]) versus segment based (using standard nonlinear least square fitting) method for model fitting, respectively. Differences between linear versus nonlinear least square approaches have been assessed using single-tissue compartmental modelling and demonstrated that linear least square methods may compromise the accuracy of MBF quantification [26], [35]. In contrast, other studies showed that the linear least square and/or generalised linear least square (designed to reduce estimation bias of the linear least square method) approaches can provide accurate estimates of blood flow, compared to the standard nonlinear least square (segment based) method [36], [37], [38]. Boellaard *et al.* compared different methods for pixel based MBF analysis and demonstrated that the basis function method was independent of the noise level and provided the most accurate perfusion estimates, compared to the linear least square and generalised linear least square approaches [39]. Further work is needed to elucidate to what degree the linear least square approach used has affected the diagnostic performance of the Carimas software. Another important difference in the post-processing between Carimas and PMOD is the 2-step versus 1-step mathematical modelling, respectively. This involves fitting different operational equations for the two softwares and thus, MBF estimations differ: MBF is indirectly estimated through the fitted parameter K_1' in Carimas (described in Methods, Table I and Carimas documentation), whilst directly calculated from the fitted parameter MBF in PMOD. These disparities can suggest that any Carimas-derived MBF overestimations may be due to a combination of the above technical differences, beyond just methodological differences in the spill-over correction approach.

B. DCE-MR versus ^{15}O -water PET

We demonstrated for the first time strong correlations between DP/Fermi modelling- (from DCE-MRI) versus Carimas/PMOD modelling-derived values (from ^{15}O -water PET) in a subgroup of patients with CAD. This is also the first study comparing DP modelling against PET. In per segment based analysis, we showed that haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD were comparable for DP and PMOD, against Fermi and Carimas analysis. Due to the small number of subjects in this subgroup of patients, it was not possible to perform a full diagnostic performance comparison (ROC analysis) for obstructive CAD detection across all our MR versus PET comparisons. However, our PET findings are consistent with the higher haemodynamic differences presented in our full

cohort for PMOD in per segment level, for which superior diagnostic performances were consistently demonstrated against Carimas. Similarly, our MR findings are also consistent with the higher haemodynamic differences showed in our previous study for DP modelling in per segment level [12], for which higher diagnostic performances were consistently shown, against Fermi modelling.

Direct comparisons in correlation coefficients against previous MR versus PET studies are difficult because of variations in the image acquisition and analysis techniques [18], [19], [40], [41], [42]. However, our correlation coefficients compare favourably against previous studies comparing two-compartmental and Fermi MR-derived MBF against PET [19], [40] respectively, whilst are in agreement with other studies that assessed model-independent, model-independent/Fermi and single-tissue compartment/Patlak MR derived MBF against PET [18], [41], [42] respectively. Two studies have previously compared DCE-MRI against ^{15}O -water PET data in healthy subjects [40], [42]. Pärkkä *et al.* [40], used 18 healthy volunteers and showed weaker perfusion correlations compared to our data analysis. Despite the larger healthy volunteer cohort used in this study, it was not possible to investigate correlations across different haemodynamic states (MBF at stress in no, minor, non-obstructive, obstructive CAD, MBF at rest), assessed in our pilot cohort. Also for the MR analysis, the parameter K^{trans} was estimated from which a direct estimate of MBF is not possible, as its physiological interpretation reflects a mixture of blood flow and the permeability surface area product [17]. Our correlation coefficients agree with the study by Tomiyama *et al.* [42], which showed strong correlations between single-tissue compartment model (per vessel analysis across 10 subjects, $r=0.92$) and Patlak model (per vessel analysis across 10 subjects, $r=0.80$) derived MBF against an in-house software for ^{15}O -water PET data analysis.

Although PET imaging is considered the reference standard for MBF quantification and therefore it is important for validating MR perfusion, each tracer has its own limitations [2], [5], [6]. The main limitations for the analysis of ^{15}O -water are the need to correct for the high ^{15}O -water activity in the blood pool and for the spill-over from the left and right ventricles [2], [5]. Our multi-modal comparisons against invasive methods showed that PMOD may be able to effectively minimise the impact of the above limitations for MBF quantification compared to Carimas, and that it may be a useful analysis tool for validating quantitative MR perfusion.

DP modelling did not show significant differences against Carimas and PMOD estimates for MBF at stress, but significantly overestimated MBF at rest (see Fig. 5b). Fermi modelling showed strong correlations against PMOD and Carimas, but it significantly overestimated MBF values, compared to all other modelling applications (Table V, Fig. 5d). These MR-derived MBF overestimations are in agreement with previous studies demonstrating rest [19] and stress-rest overestimations [41] compared with PET estimates. Further work needs to be done to assess which methodological disparities may cause consistent differences in MBF quantification between MR and PET [18], [19], [40], [41], [42], [43] and to what degree these can affect the diagnostic performance of quantitative MR and PET protocols.

C. Study limitations

Our diagnostic performance comparison between Carimas and PMOD was performed in a small pilot cohort. However, this is the first study comparing the diagnostic ability of different PET perfusion analysis software for detecting reduced MBF in obstructive CAD, which showed considerable differences between the two techniques. Any changes in the acquisition protocol, the ^{15}O -water dose or the reconstruction technique would necessitate a diagnostic performance re-assessment for both MBF quantification techniques [2], [6]. Our MR versus PET analysis was assessed in a small subgroup of patients. For DCE-MRI, we used a single bolus protocol that may be prone to arterial input function saturation effects at the peak of contrast enhancement, which can lead to MBF overestimations [10], [28]. Arterial input function saturation could be more pronounced in our 3T data, compared to perfusion data from 1.5T. Our group previously demonstrated that DP modelling is less dependent on arterial input function saturation compared to Fermi modelling (at 3T) [12]. Fermi modelling may derive smaller systematic bias against PET compared to our findings, if either dual bolus protocols [28] and/ or 1.5T [10] would be used for minimising signal saturation. Despite any Fermi-derived overestimations due to arterial input function saturation effects, our findings are consistent with other studies which showed that Fermi estimates were systematically increased compared to DP modelling (at 3T) [12], to model-independent, two-compartmental and Patlak model analysis (mixture of 1.5 and 3T were used) [44] as well as to uptake model and model-independent analysis (at 1.5T) [10].

V. CONCLUSIONS

In conclusion, we demonstrated consistently superior diagnostic performance for the detection of obstructive CAD when PMOD was used versus Carimas in ^{15}O -water PET data. Although we showed strong, significant cross-correlations between MR against PET quantitative perfusion analysis, PMOD and DP analysis detected comparable and higher haemodynamic differences between obstructive versus (no, minor or non)-obstructive CAD, compared to Carimas and Fermi analysis.

Our MR method assessments against the optimum PET reference standard technique for perfusion analysis showed promising results in per segment level and can support further multi-modality assessments in larger patient cohorts. Further MR versus PET assessments may help to determine the comparative diagnostic performance of both quantitative methodologies for obstructive CAD detection.

ACKNOWLEDGMENT

The authors are grateful to Siemens Gmbh for supplying the works in progress software and to the radiographers of the Clinical Research Imaging Centre for their contributions to the image acquisition protocols.

REFERENCES

1. C. Jaarsma, T. Leiner, S. C. Bekkers, H. J. Crijns, J. E. Wildberger, E. Nagel, P.J. Nelemans, and S. Schalla, "Diagnostic performance

- of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease," *J Am Coll Cardiol.*, vol. 59, no. 19, pp. 1719–28, May 2012.
2. J. Knuuti, S. Kajander, M. Mäki, and H. Ukkonen, "Quantification of myocardial blood flow will reform the detection of CAD," *J Nucl Cardiol.*, vol. 16, no. 4, pp. 497–506, Aug. 2009.
 3. A. R. Patel, P.F. Antkowiak, K.R. Nandalur, A.M. West, M. Salerno, V. Arora, J. Christopher, F.H. Epstein, and C.M. Kramer, "Assessment of advanced coronary artery disease: advantages of quantitative cardiac magnetic resonance perfusion analysis," *J Am Coll Cardiol.*, vol. 56, no. 7, pp. 561–69, Aug. 2010.
 4. H. J. Harms, P. Knaapen, S. de Haan, R. Halbmeijer, A. A. Lammertsma, and M. Lubberink, "Automatic generation of absolute myocardial blood flow images using [¹⁵O]H₂O and a clinical PET/CT scanner," *Eur J Nucl Med Mol. Imaging*, vol. 38, no. 5, pp. 930–9, May 2011.
 5. A. Bol, J. A. Melin, J. L. Vanoverschelde, T. Baudhuin, D. Vogelaers, P. M. D. Pauw et al, "Direct comparison of [¹³N]ammonia and [¹⁵O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres," *Circulation*, vol. 87, no. 2, pp. 512–25, Feb. 1993.
 6. H. Iida, I. Kanno, A. Takahashi, S. Miura, M. Murakami, K. Takahashi, Y. Ono, F. Shishido, A. Inugami, and N. Tomura, "Measurement of absolute myocardial blood flow with H₂¹⁵O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect," *Circulation*, vol. 78, no. 1, pp. 104–15, Jul. 1988.
 7. S. V. Nesterov, C. Han, M. Maki, S. Kajander, A. G. Naum, H. Helenius, I. Lisinen, H. Ukkonen, M. Pietilä, E. Joutsiniemi, and J. Knuuti, "Myocardial perfusion quantitation with ¹⁵O-labelled water PET: high reproducibility of the new cardiac analysis software (Carimas)," *Eur J Nucl Med Mol Imaging*, vol. 36, no. 10, pp. 1594–602, Apr. 2009.
 8. I. Danad, P. G. Raijmakers, Y. E. Appelman, H. J. Harms, S. de Haan, M. L. van den Oever, M. W. Heymans, I.I. Tulevski, C. van Kuijk, O. S. Hoekstra, A. A. Lammertsma, M. Lubberink, A. C. van Rossum, and P. Knaapen, "Hybrid Imaging Using Quantitative H₂¹⁵O PET and CT-Based Coronary Angiography for the Detection of Coronary Artery Disease," *J Nucl Med.*, vol. 54, no.1, pp. 55–63, Jan. 2013.
 9. H. J. Harms, S. V. Nesterov, C. Han, I. Danad, R. Leonora, P. G. Raijmakers, A. A. Lammertsma, J. Knuuti, and P. Knaapen, "Comparison of clinical non-commercial tools for automated quantification of myocardial blood flow using oxygen-15-labelled water PET/CT," *Eur Heart J Cardiovasc Imaging*, vol. 15, no. 4, pp. 431–41, Apr. 2014.
 10. J. D. Biglands, D. R. Magee, S. P. Sourbron, S. Plein, J. P. Greenwood, and A. Radjenovic, "Comparison of the diagnostic performance of four quantitative myocardial perfusion estimation methods used in cardiac MR imaging," *Radiol.*, vol. 275, no. 2, pp. 393–402, May 2015.
 11. A. Huber, S. Sourbron, V. Klauss, J. Schaefer, K. U. Bauner, M. Schwyer, M. Reiser, E. Rummeny, and J. Rieber, "Magnetic resonance perfusion of the myocardium: Semiquantitative and quantitative evaluation in comparison with coronary angiography and fractional flow reserve," *Invest Radiol.*, vol. 47, no. 6, pp. 332–8, Jun. 2012.
 12. G. Papanastasiou, M. C. Williams, M. R. Dweck, S. Alam, A. Cooper, S. Mirsadraee, D.E. Newby, and S.I. Semple, "Quantitative assessment of myocardial blood flow in coronary artery disease by cardiovascular magnetic resonance: comparison of Fermi and distributed parameter modelling against invasive methods," *J Cardiovasc Magn Reson.*, vol. 18, no. 1, pp. 1–13, Sep. 2016.
 13. S. A. Kajander, E. Joutsiniemi, M. Saraste, M. Pietilä, H. Ukkonen, A. Saraste, H. T. Sipilä, M. Teras, M. Maki, J. Airaksinen, J. Hartiala, and J. Knuuti, "Clinical value of absolute quantification of myocardial perfusion with ¹⁵O-water in coronary artery disease," *Circ Cardiovasc Imaging.*, vol. 4, no. 6, pp. 678–84, Nov. 2011.
 14. V. Berti, R. Sciarà, D. Neglia, M. Pietilä, A. J. Scholte, S. Nekolla, F. Rouzet, A. Pupi, and J. Knuuti, "Segmental quantitative myocardial perfusion with PET for the detection of significant coronary artery disease in patients with stable angina," *Eur J Nucl Med Mol Imaging.*, vol. 43, no. 8, pp. 1–8, Jul. 2016.
 15. M. M. Hajjiri, M. B. Leavitt, H. Zheng, A. E. Spooner, A.J. Fischman, and H. Gewirtz, "Comparison of positron emission tomography measurement of adenosine-stimulated absolute myocardial blood flow versus relative myocardial tracer content for physiological assessment of coronary artery stenosis severity and location," *J Am Coll Cardiol Img.*, vol. 2, no. 6, pp. 751–8, Jun. 2009.
 16. D. A. Broadbent, J. D. Biglands, A. Larghat, S. P. Sourbron, A. Radjenovic, J. P. Greenwood, S. Plein, and D. L. Buckley, "Myocardial blood flow at rest and stress measured with dynamic contrast-enhanced MRI: Comparison of a distributed parameter model with a fermi function model," *Magn Reson Med.*, vol. 70, no. 6, pp. 1591–7, Feb. 2013.
 17. S. P. Sourbron, and D. L. Buckley, "Tracer kinetic modeling in MRI: estimating perfusion and capillary permeability," *Phys Med Biol.*, vol. 57, no. 2, pp. R1–R33, Jan. 2012.
 18. C. A. Miller, J. H. Naish, M.P. Ainslie, C. Tonge, D. Tout, P. Arumugam, A. Banerji, R. M. Egdel, D. Clark, P. Weale, C.D. Steadman, G. P. McCann, S.G. Ray, G. J. M. Parker, and M. Schmitt, "Voxel-wise quantification of myocardial blood flow with cardiovascular magnetic resonance: effect of variations in methodology and validation with positron emission tomography," *J Cardiovasc Magn Reson.*, vol.16, no. 1, pp. 11. Jan. 2014.
 19. G. Morton, A. Chiribiri, M. Ishida, S. T. Hussain, A. Schuster A, A. Indermuehle, D. Perera, J. Knuuti, S. Baker, E. Hedstrom, P. Schleyer, M. O'Doherty, S. Barrington, and E. Nagel, "Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography," *J Am Coll Cardiol.*, vol. 60, no. 16, pp. 1546–55, Oct. 2012.
 20. M. C. Williams, S. Mirsadraee, M. R. Dweck, N. W. Weir, A. Fletcher, C. Lucatelli, T. MacGillivray, S. K. Golay, N. L. Cruden, P. A. Henriksen, N. Uren, G. McKillop, J. A. C. Lima, J. H. Reid, E. J. R. van Beek, D. Patel, and D. E. Newby, "Computed tomography myocardial perfusion vs ¹⁵O-water positron emission tomography and fractional flow reserve," *Eur Radiol.*, vol. 27, no. 3, pp. 1114–24, Jun. 2016.
 21. D. R. Messroghli, A. Greiser, M. Fröhlich, R. Dietz, and J. Schulz-Menger J, "Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart," *J Magn Reson Im.*, vol. 26, no. 4, pp. 1081–6, Oct. 2007.
 22. M. D. Cerqueira, N. J. Weissman, V. Dilsizian, A. K. Jacobs, S. Kaul, W. K. Laskey, D. J. Pennell, J. A. Rumberger, T. Ryan, and M. S. Verani, "Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart: A Statement for Healthcare Professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association," *Circulation.* vol. 105, no. 4, pp. 539–42, Jan. 2002.
 23. P. A. L. Tonino, W. F. Fearon, B. De Bruyne, K. G. Oldroyd, M. A. Leesar, P. N. Ver Lee, P. A. Maccarthy, M. Van't Veer, and N. H. Pijls, "Angiographic versus functional severity of coronary artery stenoses in the FAME study," *J Am Coll Cardiol.*, vol. 55, no. 25, pp. 2816–21, Jun. 2010.
 24. I. Adachi, O. Gaemperli, I. Valenta, T. Schepis, P. T. Siegrist, V. Treyer, C. Burger, K. Morita, and P. A. Kaufmann, "Assessment of myocardial perfusion by dynamic O-15-labeled water PET imaging: validation of a new fast factor analysis," *J Nucl Cardiol.*, vol. 14, no. 5, pp. 698–705, Oct. 2007.
 25. F. Hermansen, S. D. Rosen, F. Fath-Ordoubadi, J. S. Kooner, J. C. Clark, P. G. Camici, and A. A. Lammersma, "Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols," *Eur J Nucl Med.*, vol. 25, no. 7, pp. 751–759, Jul. 1998.
 26. G. Blomqvist, "On the construction of functional maps in positron emission tomography," *J. Cereb. Blood Flow Metab.*, vol. 4, no. 4, pp. 629–632, Dec. 1984.
 27. H. B. W. Larsson, T. Fritz-Hansen, E. Rostrup, L. Søndergaard, P. Ring, and O. Henriksen, "Myocardial perfusion modeling using MRI," *Magn Reson Med.*, vol. 35, no. 5, pp. 716–26, May 1996.
 28. G. Papanastasiou, M. C. Williams, L. E. Kershaw, M. R. Dweck, S. Alam, S. Mirsadraee, M. Connell, C. Gray, T. MacGillivray, D. E. Newby, and S.I. Semple, "Measurement of myocardial blood

- flow by magnetic resonance perfusion imaging: comparison of distributed parameter and Fermi models with single and dual bolus", *J Cardio Magn Reson.*, vol. 17, no. 17, pp. 1-10, Feb. 2015.
29. M. Jerosch-Herold, N. Wilke, and A. E. Stillman, "Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution," *Med Phys.*, vol. 25, no. 1, pp. 73–84, Jan. 1998.
 30. A. Garpebring, N. Ostlund, and M. Karlsson, "A novel estimation method for physiological parameters in dynamic contrast-enhanced MRI: application of a distributed parameter model using Fourier-domain calculations," *IEEE Trans Med Imaging.*, vol. 28, no. 9, pp. 1375-83, Sep. 2009.
 31. E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach," *Biometrics.*, vol. 44, no. 3, pp. 837–45, Sep. 1988.
 32. S. V. Nesterov, E. Deshayes, R. Sciacrà, L. Settimo, J. M. Declerck, et al, "Quantification of myocardial blood flow in absolute terms using ^{82}Rb PET imaging: the RUBY-10 study," *JACC Cardiovasc Imaging.*, vol. 7, no. 11, pp. 1119–27, Nov. 2014.
 33. I. Danad, V. Uusitalo, T. Kero, A. Saraste, P. G. Raijmakers, A. A. Lammertsma, M. W. Heymans, S. A. Kajander, M. Pietilä, S. James, J. Sörensen, P. Knaapen, and J. Knuuti, "Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative [(15)O]H₂O PET imaging," *J Am Coll Cardiol.*, vol. 64, no. 14, pp. 1464–75, Oct. 2014.
 34. T. D. Karamitsos, L. Leccisotti, J. R. Arnold, A. Recio-Mayoral, P. Bhamra-Ariza, R. K. Howells, N. Searle, M. D. Robson, O. E. Rimoldi, P. G. Camici, S. Neubauer, and J. B. Selvanayagam, "Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography," *Circ Cardiovasc Imaging.*, vol. 3, no. 1, pp. 32–40, Jan. 2010.
 35. A. A. Lammertsma, R. De Silva, L. I. Araujo, and T. Jones, "Measurement of regional myocardial blood flow using C15O₂ and positron emission tomography: comparison of tracer models," *Clin Phys Physiol Meas.*, vol. 13, no. 1, pp. 1–20, Jan. 1992.
 36. D. Feng, Z. Wang, and S. C. Huang, "A study on statistically reliable and computationally efficient algorithms for the measurement of local cerebral blood flow with positron emission tomography," *IEEE Trans Med Imaging.*, vol. 12, pp. 182-188, Jun. 1993.
 37. K. Chen, M. Lawson, E. Reiman, et al. "Generalized linear least squares method for fast generation of myocardial blood flow parametric images with N-13 ammonia PET," *IEEE Trans Med Imaging.*, vol. 17, pp. 236-243, Apr. 1998.
 38. J.S. Lee, D.S. Lee, J.Y. Ahn, et al. "Generation of parametric image of regional myocardial blood flow using H(2)(15)O dynamic PET and a linear least-squares method," *J Nucl Med.*, vol. 46, no. 10, pp. 1687–95, Jul. 2005.
 39. R. Boellaard, P. Knaapen, A. Rijbroek, G. J. Luurtsema, and A. A. Lammertsma, "Evaluation of basis function and linear least squares methods for generating parametric blood flow images using 15O-water and positron emission tomography," *Mol Imaging Biol.*, vol. 7, no. 4, pp. 273–85, Jul. 2005.
 40. J. P. Pärkkä, P. Niemi, A. Saraste, J. W. Koskenvuo, M. Komu, V. Oikonen, J. O. Toikka, T. O. Kiviniemi, J. Knuuti, H. Sakuma, and J. J. Hartiala, "Comparison of MRI and positron emission tomography for measuring myocardial perfusion reserve in healthy humans," *Magn Reson Med.*, vol. 55, no. 4, pp. 772–9, Feb. 2006.
 41. N. A. Pack, E. V. R. DiBella, T. C. Rust, D. J. Kadrmas, C. J. McGann, R. Butterfield, P. E. Christian, and J. M. Hoffman, "Estimating myocardial perfusion from dynamic contrast-enhanced CMR with a model independent deconvolution method," *J Cardiovasc Magn Reson.*, vol. 10, no. 1, pp. 1-15, Nov. 2008.
 42. Y. Tomiyama, O. Manabe, N. Oyama-Manabe, M. Naya, H. Sugimori, K. Hirata, Y. Mori, H. Tsutsui, K. Kudo, N. Tamaki, and C. Katoh, "Quantification of myocardial blood flow with dynamic perfusion 3.0 Tesla MRI: Validation with (15) O-water PET," *J Magn Reson Imaging.*, vol. 42, no.1, pp. 754-62, Sep 2015.
 43. T. Fritz-Hansen, J. D. Hove, K. F. Kofoed, H. Kelbaek, and H. B. Larsson, "Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography," *J Magn Reson Imaging.*, vol. 27, no. 4, pp. 818–24, Apr. 2008.
 44. N.A. Pack, and E. V. R. DiBella, "Comparison of myocardial perfusion estimates from dynamic contrast-enhanced magnetic resonance imaging with four quantitative analysis methods," *Magn Reson Med.*, vol. 64, no. 1, pp. 125–37, Jul. 2010.